Core Points - Transgene has requested the suspension of trading of its shares on Euronext Paris pending the publication of the results of its capital increase, with trading set to resume on 27 November 2025 [1] Company Overview - Transgene is a biotechnology company focused on developing targeted immunotherapies for cancer treatment, with a portfolio of viral vector-based immunotherapeutics [2] - The company's lead asset is TG4050, an individualized therapeutic vaccine based on the myvac® platform, which has shown proof of principle in treating head and neck cancers [2] - Transgene is also developing other viral vector-based assets, including BT-001, an oncolytic virus in clinical development, and is engaged in innovative discovery and preclinical work for novel viral vector-based modalities [2] Technology and Innovation - The myvac® platform allows for the creation of personalized virus-based immunotherapies that encode patient-specific mutations identified through advanced AI technologies [3] - Transgene's proprietary Invir.IO® platform is aimed at designing a new generation of multifunctional oncolytic viruses, leveraging the company's expertise in viral vector engineering [4]

Core Points - Transgene successfully raised approximately €105 million through a fundraising initiative involving private placements and retail offerings at a price of €1.02 per share [1][6][10] - The funds will primarily support the development of the myvac® platform, which focuses on individualized therapeutic vaccines for cancer treatment [4][5][7] - The fundraising included participation from specialized healthcare investors and existing shareholders, indicating strong institutional interest [2][21] Fundraising Details - The fundraising consisted of a private placement and a public offering via the PrimaryBid platform, with a total of 141,433,349 new ordinary shares issued, representing 106.5% of the company's current share capital [9][10] - The subscription price of €1.02 per share reflects a 25% discount compared to the closing price prior to the fundraising [10] - A reserved capital increase of €39,262,015.44 was also conducted for TSGH, utilizing amounts advanced under a current account advance agreement [3][12] Use of Proceeds - Approximately 70% of the net proceeds will be allocated to accelerate the myvac® program, including ongoing Phase 2 trials and the launch of new indications [7][5] - About 20% will be directed towards R&D costs related to the myvac® program and other clinical trials [7] - The remaining funds will cover general administrative expenses and recurring cash consumption [7] Expected Milestones - Key milestones include the completion of the ongoing Phase 2 trial in head and neck cancers, with results anticipated by late 2027 or early 2028 [4][15] - The company plans to launch a Phase 1 trial in a new indication and prepare for pivotal trials by the end of 2027 [15][4] Share Capital and Ownership Structure - Post-fundraising, the company's share capital will amount to €82,256,012.70, divided into 274,186,709 ordinary shares [18] - TSGH will hold 78.29% of the capital, while SITAM Belgium will hold 3.55%, with other shareholders comprising 18.16% [18][21] Trading and Regulatory Information - Trading of Transgene's shares on Euronext Paris was suspended during the fundraising and is set to resume on November 27, 2025 [23][24] - The new shares will be fungible with existing shares and will carry the same rights [25]

Core Points - Transgene has requested a suspension of trading for its shares on Euronext Paris starting November 26, 2025, pending the announcement of its capital increase results [1] - Trading is expected to resume on November 27, 2025, at market opening [1] Company Overview - Transgene is a biotechnology company focused on developing immunotherapy products for cancer treatment, with a portfolio that includes several viral vector-based immunotherapies in clinical development [2] - The lead candidate, TG4050, is the first individualized treatment from the myvac® platform, showing clinical proof of concept in patients with head and neck cancer [2] - Other candidates in development include BT-001, an oncolytic virus based on the patented invir.IO® platform [2] Technology and Innovation - The myvac® platform integrates tumor mutations identified through artificial intelligence into a viral vector, marking a step into precision medicine [3] - The invir.IO® platform allows for the design of multifunctional oncolytic viruses, showcasing Transgene's expertise in viral vector engineering [3]

Core Points - Transgene has requested a suspension of trading for its shares on Euronext Paris pending the publication of results from its capital increase [1] - Trading is expected to resume on November 27, 2025, at the market opening [1] Company Overview - Transgene is a biotechnology company focused on developing immunotherapy products for cancer treatment [2] - The company's lead candidate, TG4050, is an individualized treatment that has shown clinical proof of concept in patients with head and neck cancer [2] - Transgene is also developing other candidates, including BT-001, which is based on a patented oncolytic virus [2] Technology Platforms - The myvac® platform allows for patient-specific immunotherapy by integrating tumor mutations identified through artificial intelligence [3] - The invir.IO® platform enables the design of multifunctional oncolytic viruses, showcasing Transgene's expertise in viral vector engineering [3]

Core Viewpoint - Transgene has requested a suspension of trading for its shares on Euronext Paris pending the announcement of its capital increase results, with trading expected to resume on November 27, 2025 [1] Company Overview - Transgene is a biotechnology company focused on developing immunotherapy products for cancer treatment, with a portfolio that includes several viral vector-based immunotherapies currently in clinical development [3] - The lead candidate, TG4050, is the first individualized treatment from the myvac® platform, showing clinical proof of concept in patients with head and neck cancer [3] - Other candidates in development include BT-001, an oncolytic virus based on the patented invir.IO® platform [3] Technology and Innovation - The myvac® platform integrates tumor mutations identified through artificial intelligence into a viral vector, marking a step into precision medicine [4] - The invir.IO® platform allows for the design of a new generation of multifunctional oncolytic viruses, showcasing Transgene's expertise in viral vector engineering [4]

Core Points - Transgene is launching a fundraising initiative to raise approximately €105 million through the issuance of new shares to specialized investors via private placement and to retail investors via the PrimaryBid platform [1][4][6] - The funds raised will primarily accelerate the development of the myvac® program, which focuses on individualized cancer vaccines, particularly for head and neck cancer [3][4][7] - The company anticipates that the net proceeds from the fundraising, combined with existing cash, will be sufficient to meet working capital requirements until early 2028 [5][9] Fundraising Details - The fundraising consists of a private placement aimed at international institutional investors and a public offering for retail investors, with TSGH committing to subscribe for at least €70 million [6][10] - A concurrent capital increase of approximately €39.4 million is reserved for TSGH, which will be executed at the same price as the private placement and PrimaryBid offering [2][32] - The private placement and PrimaryBid offering are expected to close on 26 November 2025, with trading of Transgene shares suspended on that day [6][29][20] Use of Proceeds - Approximately 70% of the net proceeds will be allocated to accelerate the myvac® program, including ongoing clinical trials and manufacturing optimization [7][4] - About 20% will be used for R&D costs related to the myvac® program and other clinical trials, while the remainder will cover general administrative expenses [7][4] Financial Position - Prior to the fundraising, Transgene had €11.1 million in cash and a drawing capacity of €8.7 million on the Current Account Advance [8] - Following the completion of the Reserved Capital Increase, the Current Account Advance Agreement will be terminated, enhancing the company's financial stability [9][32] Expected Milestones - Key milestones for the myvac® platform include reporting important data in 2026 and 2027, with potential initiation of a Phase 3 trial in head and neck cancer [3][11][13]

Core Points - Transgene is launching a fundraising initiative to raise approximately €105 million through the issuance of new shares, targeting specialized investors via private placement and retail investors through the PrimaryBid platform [2][6] - The company aims to accelerate the development of its myvac® platform, particularly the individualized cancer vaccine TG4050, which has shown promising results in patients with operable head and neck cancer [4][5] - The funds raised will extend the company's financial visibility until early 2028, allowing for ongoing clinical trials and preparation for potential pivotal trials [6][8] Fundraising Details - The fundraising consists of a private placement for institutional investors and a public offering for retail investors, with TSGH committing to invest at least €70 million [11][14] - The private placement and PrimaryBid offering will close on November 26, 2025, with trading of Transgene shares suspended on that day [6][32] - The net proceeds from the fundraising will be allocated primarily to the myvac® program (approximately 70%), followed by R&D costs (approximately 20%), and general operational expenses [7][8] Financial Position - Prior to the fundraising, Transgene had €11.1 million in cash and a drawing capacity of €8.7 million on its Current Account Advance [9] - Following the fundraising, the company expects to meet its working capital requirements until early 2028, significantly improving its financial stability [10][8] - The Reserved Capital Increase of approximately €39.4 million will be executed at the same price as the private placement, converting debt into equity and strengthening the company's balance sheet [34][36] Expected Milestones - Key milestones for the myvac® platform include follow-up data from ongoing trials in head and neck cancers, with significant data expected in 2026 and 2027 [13] - The company plans to launch a Phase 1 trial in a new indication once financing conditions are met, with preparations for late-stage trials expected to conclude by the end of 2027 [12][13] Shareholder Structure - As of the date of the press release, TSGH holds 68.87% of the company's share capital, and after the fundraising, its stake is expected to decrease slightly to 68.06% [28][29] - The fundraising will result in dilution for existing shareholders, with the shareholding percentage for a shareholder holding 1% of the capital before the fundraising expected to drop to approximately 0.63% post-issuance [27]

PresentationI'd now like to turn the call over to Lucie Larguier. Please go ahead, Lucie.Good morning, and welcome to the Transgene conference call. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Transgene website following the event.Lucie LarguierVP & Chief Financial Officer Thank you, Tara, and hello, everyone. Thanks for joining us on today's call, and we will discuss our new TG4050 Phase I immunological data. Today, you will have the opport ...

Core Insights - Transgene is set to present its proprietary computational tool, VacDesignR®, at the ESMO AI & Digital Oncology 2025 conference, which enhances the design and production of recombinant Modified Vaccinia Ankara (MVA)-based vectors for individualized neoantigen therapeutic vaccines [1][2][5] Group 1: VacDesignR® Tool - VacDesignR® optimizes recombinant plasmid architecture for MVA vectors, improving production reliability and vector quality by minimizing unwanted homologous recombination and intelligently selecting peptide sequences [3] - Future versions of VacDesignR® will integrate AI components to enhance performance and scalability, aligning with Transgene's strategy to expedite production timelines for individualized therapeutic vaccines [4] Group 2: Clinical Development - The individualized immunotherapies developed through the myvac® platform are currently in a Phase I/II clinical trial (NCT04183166), utilizing the VacDesignR® tool for their design [2] - TG4050, the first individualized therapeutic vaccine based on the myvac® platform, is designed to treat HPV-negative head and neck cancers following surgery and adjuvant therapy [4][8] Group 3: Company Overview - Transgene focuses on designing and developing virus-based immunotherapies for cancer treatment, with a portfolio that includes viral vector-based immunotherapeutics [8] - The myvac® platform allows for the creation of personalized immunotherapies that encode patient-specific mutations, utilizing advanced AI technologies [9]

Core Insights - Transgene's TG4050, an individualized neoantigen therapeutic vaccine, shows promising immunogenicity data in preventing cancer relapse, with results to be presented at SITC 2025 [1][2][3] - The company is advancing its clinical trials, with the first immunogenicity data from the ongoing Phase II trial expected in H2 2026 [1][6] - Financial updates indicate a positive trend in research tax credits and a strategic funding plan to support operations until the end of December 2026 [12][14][15] Clinical Development - TG4050 has demonstrated the ability to induce neoantigen-specific cytotoxic CD8+ T-cell responses, which can target and eliminate tumor cells, with effects detectable up to two years post-treatment [3][4] - The ongoing Phase I/II trial evaluates TG4050 as a single agent in the adjuvant treatment of HPV-negative head and neck squamous cell carcinoma (HNSCC) [4][6] - Transgene is exploring efficient regulatory pathways to expedite TG4050's development for operable HNSCC patients [7] Financial Position - For Q3 2025, Transgene reported a research tax credit of €5.8 million, up from €4.8 million in Q3 2024, reflecting ongoing clinical trial progress [12] - As of September 30, 2025, the company had €12.8 million in cash, down from €16.7 million at the end of 2024, with a net cash burn of €28.8 million for the first nine months of 2025 [13] - A new amendment to the account advance agreement with major shareholder TSGH has increased funding to €48 million, allowing the company to sustain operations through December 2026 [14][15] Future Plans - Transgene plans to present additional immunological data profiling the neoantigen-specific T-cell response at the SITC Annual Meeting [2][5] - The company is initiating start-up activities for a potential new Phase I trial in a second indication, aiming to begin once all conditions are met [8]